Detalles de la búsqueda
1.
Population pharmacokinetics and exposure-response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma.
Br J Clin Pharmacol;
89(5): 1640-1655, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36484341
2.
Improving categorical endpoint longitudinal exposure-response modeling through the joint modeling with a related endpoint.
J Pharmacokinet Pharmacodyn;
49(3): 283-291, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34800232
3.
Combined exome sequencing and deep phenotyping in highly selected fetuses with skeletal dysplasia during the first and second trimesters improves diagnostic yield.
Prenat Diagn;
41(11): 1401-1413, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34091931
4.
A novel quantification of information for longitudinal data analyzed by mixed-effects modeling.
Pharm Stat;
19(4): 388-398, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31989784
5.
Development and Translational Application of a Minimal Physiologically Based Pharmacokinetic Model for a Monoclonal Antibody against Interleukin 23 (IL-23) in IL-23-Induced Psoriasis-Like Mice.
J Pharmacol Exp Ther;
365(1): 140-155, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29420255
6.
Full covariate modelling approach in population pharmacokinetics: understanding the underlying hypothesis tests and implications of multiplicity.
Br J Clin Pharmacol;
84(7): 1525-1534, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29522646
7.
Noninvasive prenatal test for FGFR3-related skeletal dysplasia based on next-generation sequencing and plasma cell-free DNA: Test performance analysis and feasibility exploration.
Prenat Diagn;
38(11): 821-828, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30048571
8.
Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure-response modeling of Mayo scores for golimumab in patients with ulcerative colitis.
J Pharmacokinet Pharmacodyn;
45(6): 803-816, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30377888
9.
Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumab.
J Pharmacokinet Pharmacodyn;
45(5): 679-691, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29961161
10.
A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis.
J Pharmacokinet Pharmacodyn;
45(4): 523-535, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29549540
11.
Influence of carboplatin on the proliferation and apoptosis of ovarian cancer cells through mTOR/p70s6k signaling pathway.
J BUON;
23(6): 1732-1738, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30610801
12.
Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients.
J Pharmacokinet Pharmacodyn;
44(5): 437-448, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28634654
13.
Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's disease.
J Pharmacokinet Pharmacodyn;
44(5): 425-436, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28623612
14.
Deciphering the In Vivo Performance of a Monoclonal Antibody to Neutralize Its Soluble Target at the Site of Action in a Mouse Collagen-Induced Arthritis Model.
Pharm Res;
33(4): 1040-9, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26718954
15.
First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
Eur J Clin Pharmacol;
72(11): 1303-1310, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27515978
16.
Pharmacological considerations for predicting PK/PD at the site of action for therapeutic proteins.
Drug Discov Today Technol;
21-22: 35-39, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27978986
17.
Improvement in latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint in rheumatoid arthritis.
J Pharmacokinet Pharmacodyn;
43(1): 45-54, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26553114
18.
Minimal physiologically-based pharmacokinetic (mPBPK) model for a monoclonal antibody against interleukin-6 in mice with collagen-induced arthritis.
J Pharmacokinet Pharmacodyn;
43(3): 291-304, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27119518
19.
Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
Gastroenterology;
147(6): 1296-1307.e5, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25173754
20.
Mechanisms of monoclonal antibody-drug interactions.
Annu Rev Pharmacol Toxicol;
51: 359-72, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-20936946